Investor Presentaiton
Company overview
Financial performance
Oncology
Immunology
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
Ophthalmology
Neuroscience
Respiratory Disease
JDQ443-KRAS inhibitor
NCT05132075 KontRASt-02 (CJDQ443B12301)
Indication
Non-small cell lung cancer, 2/3L
Phase
Phase 3
Patients
360
Primary
Outcome
Measures
Arms
Progression free survival (PFS)
Intervention
Target
Patients
Read-out
Milestone(s)
Arm 1 Experimental: JDQ443
Arm 2 Active Comparator: Participant will be treated with docetaxel following
local guidelines as per standard of care and product labels
Patients with advanced non-small cell lung cancer (NSCLC) harboring a
KRAS G12C mutation who have been previously treated with a platinum-
based chemotherapy and immune checkpoint inhibitor therapy either in
sequence or in combination.
2024
Publication
NA
References
Abbreviations
Cardio-Renal
Global Health
Biosimilars
51 Investor Relations | Q2 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation